Literature DB >> 9398617

Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites.

S A Cunningham1, M P Arrate, T A Brock, M N Waxham.   

Abstract

Vascular endothelial cell growth factor interacts with the receptor tyrosine kinases Flt-1 and KDR/Flk-1. We report that both receptors bind to PLC gamma and display specificity for the N-SH2 over the C-SH2 domain. Extensive site-directed mutagenesis of Flt-1 reveals that the juxta-membrane Y794, and the carboxyl terminal Y1169, are two major sites of interaction. Amino acids in the +1, +2 and +3 positions following these tyrosines are LSI and IPI, respectively. Peptide maps generated from wild type and mutant Flt-1 confirms that these residues are autophosphorylated. As predicted, mutagenesis of the analogous amino acids in KDR, positions Y801F and Y1175F, which lie in contexts YLSI and YIVL, respectively, reduced interactions of PLC gamma with this receptor. We conclude that both Flt-1 and KDR have the potential to signal through PLC gamma via phosphotyrosine residues located in juxta-membrane and carboxyl tail regions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398617     DOI: 10.1006/bbrc.1997.7719

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells.

Authors:  A J Warner; J Lopez-Dee; E L Knight; J R Feramisco; S A Prigent
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

3.  Recombinant human VEGF165b inhibits experimental choroidal neovascularization.

Authors:  Jing Hua; Christine Spee; Satoru Kase; Emma S Rennel; Anette L Magnussen; Yan Qiu; Alex Varey; Sandeep Dhayade; Amanda J Churchill; Steven J Harper; David O Bates; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-17       Impact factor: 4.799

4.  Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding.

Authors:  Y Yu; J D Hulmes; M T Herley; R G Whitney; J W Crabb; J D Sato
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

5.  A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.

Authors:  T Takahashi; S Yamaguchi; K Chida; M Shibuya
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

6.  The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.

Authors:  Benjamin A Nacev; Paola Grassi; Anne Dell; Stuart M Haslam; Jun O Liu
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

7.  Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells.

Authors:  Rosana D Meyer; Catharina Latz; Nader Rahimi
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

Review 8.  Vascular endothelial growth factors and vascular permeability.

Authors:  David O Bates
Journal:  Cardiovasc Res       Date:  2010-04-16       Impact factor: 10.787

9.  Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein.

Authors:  Ryosuke Usui; Masabumi Shibuya; Shun Ishibashi; Yoshiro Maru
Journal:  EMBO Rep       Date:  2007-10-26       Impact factor: 8.807

10.  Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells.

Authors:  Ling-Yun Chu; Devi Prasadh Ramakrishnan; Roy L Silverstein
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.